Background: Visceral adipose tissue-derived serine protease inhibitor (vaspin) has been suggested as a novel adipocytokine related to obesity and insulin sensitivity in adults. Design: We quantified vaspin serum concentrations in 65 lean and 67 obese children and aimed to evaluate the relationship of vaspin with physical development, obesity, and metabolic and cardiovascular phenotypes in children. We further assessed the acute vaspin response to glucose provocation in 20 obese adolescents and evaluated tissue expression patterns of vaspin in humans. Results: Vaspin levels were significantly higher in girls than in boys. In girls, vaspin increased with age and pubertal stage, whereas there was no change with development in boys. Obese girls had lower vaspin serum levels than those of lean controls, but there was no significant correlation with body mass index (BMI). Independent of sex, age and BMI, lower vaspin was associated with better insulin sensitivity, with higher systolic blood pressure and impaired endothelial function. In response to glucose provocation during an oral glucose tolerance test, vaspin serum levels declined by approximately 25% in adolescents with hyperinsulinemia, whereas there was no significant decline in normoinsulinemic patients. In support of our clinical data, we not only confirmed vaspin mRNA expression in adipose tissue but also found consistent expression of vaspin in the liver and indications for expression in the pancreas and the skin. Conclusion: We showed that gender differences in circulating vaspin levels develop during pubertal progression in girls. Although vaspin's association with obesity remains controversial, vaspin was increased with worsening insulin resistance already in children and was acutely down-regulated following glucose provocation in insulin-resistant adolescents independent of obesity. Besides adipose tissue, vaspin expression in the liver and the pancreas may potentially contribute to circulating vaspin levels and their regulation.
Introduction
The search for adipose tissue-derived factors, which may mediate the link between fat accumulation and obesityrelated pathology, has been receiving increasing attention. By applying a differential screening approach for genes upregulated in the visceral adipose tissue of obese Otsuka Long-Evans Tokushima Fatty rats and downregulated in nonobese and diabetes-resistant Long-Evans Tokushima Otsuka rats, Hida et al. 1 recently discovered a new adipocytokine, referred to as vaspin (visceral adipose tissue-derived serpin) in these animal models. 2 Vaspin mRNA expression in white adipose tissue (WAT) and serum levels were increased in obese animals with a maximum at the peak of their body and fat weights, and paralleling the exacerbation of insulin resistance. 1 Treatment with recombinant vaspin improved glucose tolerance and insulin sensitivity in rodents. 1 It was concluded that elevated vaspin may be a compensatory response to insulin resistance secondary to the metabolic complications of obesity. 3 In humans, some subsequent studies confirmed the association of vaspin with obesity and BMI, 4, 5 although the association was more subtle 6 or absent 7, 8 in other studies. Several studies found a positive correlation of circulating vaspin with insulin resistance indices 5, 9, 10 but not with the presence of overt type 2 diabetes. [6] [7] [8] A recent study described a marked diurnal and meal-associated pattern of circulating vaspin levels, which was reciprocal to that of insulin and glucose, and closely associated with meal ingestion. 11 These controversial observations may imply either incidental associations without causative significance or might be a phenomenon of progressive dynamics of vaspin during the transition from obesity to impaired glucose metabolism and dysregulation in diabetes. 6 Hence, despite these recent studies, the putative role of vaspin for human glucose metabolism is currently unknown. Studies in children may be of particular interest in this context, as they allow to study such associations early in the progression of obesity and related disease. 12 In addition, studies in children allow to explore potential relationships between adipokine serum concentrations, and are less biased by overt metabolic comorbidities and/or concomitant medication. We, therefore, aimed to investigate the association of vaspin with physiological changes during development in normal healthy children, to compare vaspin levels between lean and obese children and assess the association with insulin resistance and cardiovascular sequelae, and evaluated the acute response of vaspin during an oral glucose tolerance test (oGTT) in obese adolescents to assess the specific clinical interaction of vaspin with glucose/insulin metabolism. To evaluate which organ tissues contribute to vaspin serum concentrations and potential associations with glucose metabolism, we investigated the tissue expression profile of vaspin.
Materials and methods

Study subjects
We recruited 67 obese Caucasian children and adolescents and 65 lean controls of similar age, gender and pubertal stage (Table 1 ). All children were healthy and did not take any medications. Height was measured to the nearest of 0.1 cm using a stadiometer and weight to the nearest of 0.1 kg using a digital balance. Body mass index standard deviation score (BMI SDS) was calculated according to the German reference data. 13 A cut-off of X1.88 SDS (97th centile) and 1.23 SDS (90th centile) was applied to classify obesity and overweight, respectively, in children. 13 The pubertal developmental stage was evaluated according to Tanner on the basis of pubic hair development and categorized into three groups: pre-pubertal (Tanner stage PH1), pubertal (Tanner stage PH2-PH4) and adolescent (Tanner stage PH5). Bioelectrical resistance (R) was measured with a Bioelectrical Impedance Analyser Nutriguard-M (Data Input GmbH, Darmstadt, Germany) with an operating frequency of 50 kHz at 800 mA. Whole-body measurements were taken with the subject in a supine position on a non-conducting surface, with the arms slightly abducted from the trunk and the legs slightly separated. Resistance measurements were adjusted for stature, RI ¼ (height (Ht)
). Blood samples were obtained in the fasted state at 0800 hours and were immediately centrifuged, aliquoted and stored at À80 1C. Blood lipids, glucose and insulin were measured by a certified laboratory applying standard clinical biochemistry methods. 12 An oGTT was performed on all subjects. Blood samples were collected at À30, 0, 15, 30, 60, 90, 120 and 150 min after the glucose load of 1.75 g kg À1 body weight had been given (maximum of 75 g glucose).
For 24-h ambulatory blood pressure monitoring, systolic and diastolic blood pressures were recorded every 15 min during daytime (0800-1800 hours), every 20 min in the evening (1800-2200 hours) and every 30 min during nighttime (2200-0800 hours) (Spacelabs Medical Inc., Redmond, WA, USA). A recording was considered successful if 480% readings were valid.
Endothelial function was evaluated by measuring the reactive hyperemia index.
14 Pulse wave amplitude was quantified by finger plethysmography before and after 5-min forearm suprasystolic cuff-induced ischemia. Intima-media , n ¼ 10) and normal insulin response (peak insulin o600 pmol l
À1
, n ¼ 10), we analyzed vaspin serum concentrations during an oGTT.
Written informed consent was obtained from all parents and from children X12 years. The study was approved by the local ethics committee of the University of Leipzig in Germany (Reg. No. 029-2006).
Determination of circulating vaspin
Vaspin concentrations were measured by commercial enzyme-linked immunosorbent assay (ELISA), which applied a monoclonal antibody (AdipoGen, Seoul, Korea) following the manufacturer's protocol. The sensitivity was given as 12 pg ml
À1
; the inter-and intra-assay coefficients of variation were less than 10% and 5%, respectively. The quality of the assay had previously been verified by dilution and spiking experiments of human serum samples (Supplementary Table  in Youn et al. 6 ).
Analysis of tissue expression pattern of vaspin
For generation of a cDNA array, we obtained commercially available tissue RNAs (pooled and unpooled; ClontechTakara Bio Europe, Saint-Germain-en-Laye, France) and cDNAs (unpooled; Biochain GmbH, Heidelberg, Germany), and we applied a commercial multitissue cDNA array (OriGene Tissue Scan, Human Major Tissues qPCR Array, AMS Biotechnologie, Wiesbaden, Germany). In addition, we applied pre-adipocytes and adipocytes of the human SGBS cell line. 15 Reverse transcription of RNAs was performed using 200 U M-MLV reverse transcriptase per microgram of total RNA (Invitrogen, Karlsruhe, Germany) with oligo (dT) primers. Vaspin mRNA expression was determined using real-time PCR with TaqMan probe-based gene expression assay on the ABI 7500 Sequence Detection System (Applied Biosystems, Darmstadt, Germany). The following vaspin primers and probe were applied: forward:
0 . For absolute quantification, vaspin cDNA was cloned and expression plasmids were diluted to serve as standard curve. The quantification range was linear between 10 and 10E7 copies, the threshold of detection was 10 copies of vaspin cDNA (see Supplementary Material and Methods).
To normalize gene expression, b-actin, Tbp and HPRT cDNA were quantified simultaneously. The following primers and probes were used: b-actin, forward: 
Statistical analyses
The data of vaspin levels did not follow Gaussian distribution. After log-transformation (logarithm naturalis), the data fitted Gaussian distribution as evidenced by P40.2 in the Kruskal-Wallis test and visualization in quantile-quantile (Q-Q) plots. Student's test was applied for comparison of quantitative traits between two groups, univariate analysis of variance (ANOVA) for three or more groups and chi-square test for categorical data. Correlation analyses were performed using Pearson's correlation analysis or partial correlation analysis with adjustment for sex, age and BMI SDS. For multiple regression analyses, the stepwise forward model was employed. Dependent and independent variables are given in the tables.
For all tests, the two-sided significance level was set at 0.05. Statistical analyses were performed using the software package Statistica 7.1 (StatSoft, Tulsa, OK, USA).
Results
Association of vaspin with gender and development in children
We assessed the association between circulating vaspin and gender, age and pubertal stage in the healthy lean subcohort (n ¼ 65). Vaspin serum levels were significantly higher in girls than in boys (Figure 1a) . Vaspin was not associated with age or height in the entire lean cohort in unadjusted analyses. Adjusting for sex revealed a significant correlation with age (r ¼ 0.29, P ¼ 0.021) and increase of vaspin with pubertal stage (P ¼ 0.031 in ANOVA) in girls (Figures 1b and c) , whereas there was no dynamic increase of vaspin with pubertal development in boys. Consequently, the most pronounced differences between girls and boys were apparent in the adolescent age group. Neither estradiol (Figure 1d ) nor testosterone levels significantly correlated with vaspin.
Multiple regression analysis confirmed sex and age as the most important independent predictors of vaspin levels (Table 3 , Model A). Hence, vaspin increases during puberty in girls but not in boys, leading to higher levels in female adolescents.
Association of vaspin with parameters of obesity and related comorbidities Obese children had lower vaspin serum levels than those of lean controls (0.55 ± 0.06 vs 0.92 ± 0.14 ng ml
À1
, P ¼ 0.013).
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This difference between lean and obese children and adolescents was restricted to girls ( Figure 2a) . Vaspin appeared to increase with pubertal stage in the obese cohort, but this was not statistically significant ( Figure 2b ).
In consequence of obesity, HOMA-IR (1.31±0.10 vs 2.58 ± 0.18, Po0.0001) and Matsuda-ISI (8.34 ± 0.58 vs 4.39 ± 0.26, Po0.0001) were significantly different between lean and obese children, respectively. The correlation of Vaspin and glucose metabolism in children A Körner et al vaspin with insulin sensitivity parameters was weak and not significant in unadjusted analyses (Table 2) . However, the correlation between vaspin and these indices, as well as that with other insulin parameters, was significant after adjustment for sex, age and BMI SDS, and was consistent in direction (Table 2 ) with lower vaspin levels being associated with better insulin sensitivity. Concerning cardiovascular parameters, there was also a significant, but negative correlation of vaspin with blood pressure in unadjusted analyses (Table 2 ), but lower vaspin levels were associated with impaired endothelial function ( Table 2) .
In multiple regression analyses, BMI SDS contributed to the equation, but did not reach statistical significance (Table 3 , Model B). Multivariate analyses confirmed the associations of Matsuda ISI as well as 24 h systolic blood pressure with vaspin independent of sex, age and BMI SDS (Table 3 , Models C and D).
Vaspin response to oral glucose provocation
We analyzed the dynamics of vaspin serum concentrations during an oGTT in 20 obese adolescents. To allow best discrimination between insulin-resistant and insulin-sensitive patients, we specifically selected groups of hyperinsulinemic and normoinsulinemic subjects on the basis of peak insulin level during oGTT 41000 and o600 pmol l À1 , respectively. Discrimination was confirmed by the course of blood glucose and insulin during oGTT (Figures 3a and b) and, accordingly, Matsuda ISI (1.5±0.12 vs 6.4±0.83, Po0.0001) and HOMA-IR (5.48±0.67 vs 2.17±0.48, P ¼ 0.0008) were significantly impaired in the hyperinsulinemic group (1.5 ± 0.12 vs 6.4 ± 0.83, Po0.0001). There was no difference in the degree of obesity between the two groups (2.85±0.11 vs 2.58±0.20 BMI SDS, P40.2).
The course of vaspin levels was analyzed relative to basal level at À30 min. Vaspin levels significantly declined by approximately 25% in the group of hyperinsulinemic adolescents (P ANOVA ¼ 0.0010, n ¼ 9), whereas there was no significant decline in the normoinsulinemic group (Figure 3c) .
We did not identify significant correlations between vaspin levels and insulin or glucose levels at any given time point, for any group, nor across all patients and time points. Hence, in response to an oral glucose load and/or the corresponding increase in insulin, vaspin declined in insulin-resistant obese adolescents.
Tissue expression pattern of vaspin
Considering the lack of correlation with BMI and the relationship of vaspin with insulin, we evaluated mRNA expression patterns of vaspin in various human tissues from different sources.
We first applied a commercial multitissue array of 48 human tissues in which the only tissue with detectable vaspin expression was skin; liver and nasal mucosa were identified with low vaspin expression, whereas the other tissues did not express vaspin at all (Figure 4) . Overall, vaspin expression was, however, extremely low in this sample, with lack of detection in most of the tissues, and in those tissues with detectable vaspin expression, copy numbers were below 50. When we tried to verify amounts of cDNA in this sample, we identified only low amounts of b-actin cDNA, particularly for metabolic tissues of interest such as WAT, brain, heart, liver, muscle and kidney.
We, therefore, aimed to verify the non-expression of vaspin in independent tissue cDNA samples from two additional sources (Figure 4) . We confirmed vaspin expression in the liver and in two adipose tissue samples, whereas in the pancreas, vaspin expression was detectable only in one sample. In the heart, skeletal muscle and peripheral blood leukocytes, vaspin expression was only minimally above threshold and there was no detection at all in the placenta, skin fibroblasts and SGBS pre-adipocytes, or SGBS adipocytes.
Overall, we did detect low but reliable vaspin expression in the liver and in the adipose tissue, and obtained some evidence for vaspin expression in the skin and pancreas. Vaspin and glucose metabolism in children A Körner et al
Discussion
Vaspin is thought to be one of the putative adipocytokines that play a role in obesity-related metabolic disease. 3 Despite recent studies, the potential role of vaspin in human obesity and glucose metabolism is still unclear. In this study, we showed that vaspin increases with physical development in healthy lean girls, resulting in gender differences after completion of puberty. There was no clear association with obesity in children, but we provide evidence for an increase of vaspin levels with early emergence of insulin resistance in children, as well as an acute downregulation of vaspin following glucose provocation and/or subsequent hyperinsulinemia. Besides expression in WAT, we identified vaspin mRNA expression in the liver and potentially in the skin and the pancreas. Most studies found higher vaspin levels in adult women compared with men, 6, 8, [16] [17] [18] whereas others did not. 7, 9, 19 According to our data, vaspin increased with puberty in girls, but not in boys. Interestingly, vaspin was also found to be increased in patients with polycystic ovary syndrome 10 and treatment with estrogen/progesterone 20 or oral contraceptives 17 increased vaspin in polycystic ovary syndrome patients and healthy obese women. In the adipose tissue explants of polycystic ovary syndrome patients, estrogen was capable of stimulating vaspin protein expression, 10 which further supports the association of estrogen with vaspin levels. However, no significant differences in serum vaspin were found in pre-and post-menopausal women. 5 Consistently, WAT vaspin expression was unchanged in gonadectomized rats. 16 In our cohort, there was no correlation between the puberty-related sex steroids, estradiol, or testosterone. Hence, so far it is unclear where this sexual dimorphism comes from, but the association of vaspin with female sex and age must be considered in clinical studies on vaspin. We accordingly stratified subsequent analyses for sex and age. The comparison of lean and obese children revealed lower vaspin levels in obese girls compared with lean peers, but no differences in boys. There was also no association with BMI, and in multiple regression analyses BMI did not contribute to the variation of vaspin levels. From our results, we cannot, therefore, conclude that vaspin is strongly associated with obesity or BMI in children. This contradicts other studies in humans, 4, 5 although the associations were only subtle in some of them, 6, 11 and others also failed to confirm the association of vaspin with obesity. 7, 8, 18 Although most previous studies applied the same assay, it needs to be considered that discrepancies between studies may also arise from different assay systems. A previous report in children reported higher vaspin levels in obese compared with lean children, but these analyses were not adjusted for sex and puberty or age and applied a different assay. 19 Overall, it remains questionable whether vaspin is indeed associated with fat mass. In this regard it is of interest that, in contrast to the initial report, vaspin mRNA expression was not uniformly found in WAT. 9, 10, 21, 22 Hence, other sources may express vaspin and Vaspin and glucose metabolism in children A Körner et al contribute to circulating levels and their regulation. Indeed, Fain et al. 22 found vaspin mRNA enriched in non-fat cells of the stromal-vascular fraction. Also, the stomach and the placenta have been found to express vaspin mRNA in rats and humans. 21 When we systematically screened several metabolically active tissues for vaspin expression, we confirmed vaspin expression in WAT. In addition, we consistently detected vaspin expression in the liver in independent samples. We also detected noticeable expression of vaspin in the pancreas and in the skin, but were unable to confirm this in other independent samples. However, in previous reports, the vaspin mRNA expression was also not uniformly detected in all samples, 9,10 but was perceived only in a minority of samples (25% in Klöting et al.
9
). It should also be considered that the expression of vaspin is generally very low, which may explain the difficulties and the inconsistencies of tissue expression studies.
From expression studies 9 as well as clinical studies, vaspin was proposed to be related to insulin resistance. Despite the lack of association with BMI, we found a significant association with parameters of insulin resistance in our childhood cohort. This is consistent with findings in most, 5,9,10,23 though not all, adult studies. 17, 18 One explanation might be that some studies included subjects with an extreme phenotype in terms of insulin resistance and thus the metabolic effects could have overcome any potential impact of sex steroids on serum vaspin. Considering that children present a phase early in the pathological career of obesity-related comorbidities, but on the other hand are free of possibly interfering drugs, such as oral antidiabetic medications, 10, 16 our data may support the conclusion of an adaptive response of vaspin to impaired glucose metabolism. 3 The association of vaspin with metabolic parameters was robustly significant in our cohort, independent from BMI SDS and hence the degree of obesity. The explanation for this would be that vaspin is directly associated with Vaspin and glucose metabolism in children A Körner et al glucose and/or insulin metabolism as opposed to a relationship with metabolic disorders secondary to obesity. It is not clear, however, whether this potential interaction is chronic or acute and whether it is primarily mediated by glucose or insulin. To study this aspect in more detail, we analyzed vaspin levels in response to an oral glucose load in an oGTT in insulin-resistant and non-resistant obese children. In the insulin-resistant group, vaspin significantly declined during the oGTT, somehow inversely mirroring the course of insulin. This finding is coherent with the observation of a meal-related decline in vaspin levels 11, 16 and may indicate that glucose and/or insulin may have acute suppressive effects of circulating vaspin levels and/or that food-related effects such as vagal activation are involved. Tan et al. 10 identified glucose as a vaspin-releasing agent, at least in human omental adipose tissue explants, whereas Loeffelholz et al. 17 observed a (non-significant) decrease of serum vaspin under conditions of euglycemic hyperinsulinemia. In summary, these results, together with the findings of Jeong et al., 11 underscore our suggestion of an acute suppressive effect of insulin on serum vaspin. Another potential explanation would be a circadian rhythm of vaspin with a physiological peak in the morning with a subsequent circadian decline. 11 Under the light of those results, one may speculate that there is a post-prandial increase of vaspin in the insulin-sensitive group, whereas a physiological decline is found in the insulin-resistant group. To differentiate this hypothesis in more detail, a control group without glucose provocation would be desirable, which was, however, not possible to do in children. In respect to potential cardiovascular sequelae of obesity, we found that vaspin is associated with impaired endothelial function. So far, a potential relationship of vaspin with cardiovascular effects has not been investigated by in vitro or in vivo studies. However, one study in patients with extracranial carotid stenosis reported lower vaspin levels in those patients who were symptomatic as opposed to asymptomatic patients. 7 A phenomenon in our as well as other studies is the high variation of vaspin levels. This may be attributed to the systematic methodological bias of the assay, as for instance has been known for Nampt/visfatin. 24 Another explanation might be the fact that vaspin is acutely regulated by other factors, not necessarily related to obesity and metabolic disease. When screening for potential interfering associations with vaspin levels, we identified a negative correlation with thyroid hormone (data not shown). In rats, high thyroid hormone levels suppressed vaspin levels. 16 However, our study design did not allow interpreting this association. In summary, we show that the gender differences of circulating vaspin levels develop during pubertal progression in girls. Although the association of vaspin with obesity remains controversial, vaspin is increased with deteriorating insulin sensitivity independent of BMI already in children and is acutely regulated following glucose provocation in insulin-resistant subjects. Besides adipose tissue, expression in the liver and in the pancreas may potentially contribute to circulating vaspin levels and their regulation.
